Novo nordisk a/s: semaglutide 2.4 mg (wegovy®) cardiovascular outcomes data presented at american heart association scientific sessions and simultaneously published in new england journal of medicine

BagsvÆrd, denmark, 11 november 2023 – novo nordisk today announced the primary results of select, its landmark phase 3 cardiovascular outcomes trial investigating the effects of once-weekly semaglutide 2.4 mg (wegovy®) in adults with established cardiovascular disease (cvd) and overweight or obesity without diabetes at the american heart association (aha) annual scientific sessions in philadelphia. the data were simultaneously published in the new england journal of medicine (nejm). 1
NVO Ratings Summary
NVO Quant Ranking